Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program

Abstract

We analyzed the direct medical costs for Korean patients with type 2 diabetes according to the type of complications and the number of microvascular complications. We analyzed costs for type 2 diabetes and associated complications in 3,125 patients. These data were obtained from the Korean National Diabetes Program (KNDP), a large, ongoing, prospective cohort study that began in 2005. The cost data were prospectively collected, using an electronic database, for the KNDP cohort at six hospitals. The costs were analyzed according to complications for 1 yr from enrollment in the study. Among 3,125 patients, 918 patients had no vascular complications; 1,883 had microvascular complications only; 51 had macrovascular complications only; and 273 had both complications. The annual direct medical costs for a patient with only macrovascular, only microvascular, or both macrovascular and microvascular complications were 2.7, 1.5, and 2.0 times higher than the medical costs of patients without complications. Annual direct medical costs per patient increased with the number of microvascular complications in patients without macrovascular complications. The economic costs for type 2 diabetes are attributable largely to the management of microvascular and macrovascular complications. Proper management of diabetes and prevention of related complications are important for reducing medical costs.

Keywords: Diabetes Mellitus, Type 2; Direct Medical Cost; Economic Cost; Korea; Macrovascular Complications; Microvascular Complications.

Fig. 1

Annual direct medical costs per patient according to microvascular and macrovascular complications. (A) Annual direct medical cost breakdown by type of complication. (B) Cost categories contributing to annual direct medical costs per patient. (C) Cost categories contributing to outpatient costs per patient.

Fig. 2

Annual direct medical costs per patients by number of microvascular complications. (A) In patients without macrovascular complications. (B) In those with macrovascular complications. ^*P < 0.001 by ANOVA.